Dasatinib Approved in Europe for Pediatric Ph+ Chronic Phase CML

Jul 5, 2018 – The European Commission (EC) has approved dasatinib for the treatment of children and adolescent patients aged 1 to 18 years with Philadelphia chromosome–positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP), according to Bristol-Myers Squibb (BMS), the manufacturer of the tyrosine kinase inhibitor. With the action, the EC also approved a powder for an oral suspension formulation of dasatinib for use in pediatric patients and adult … (leggi tutto)